Filter by: Subject

Filter by: Subject

Results Per Page:

Positron emission tomography (PET) (7)
Prostate-specific membrane antigen (PSMA) (4)
68Ga-PSMA (2)
Cervical cancer (2)
Computed tomography (CT) (2)
Hypoxia (2)
Immunohistochemistry (2)
PET/CT (2)
Prostate carcinoma (2)
Tuberculosis (TB) (2)
18F-FDG (1)
225Ac-PSMA-617 (1)
68Ga-citrate (1)
68Ga-Nitroimidazole (1)
[68Ga]Ga-FAPI PET/CT (1)
Behandlung (1)
Bins (1)
Bioassay (1)
Biomaterials (1)
Black South-African (BSAs) (1)
Blood–brain barrier (BBB) (1)
Bone SPECT-CT (1)
Breast cancer (1)
Characterization (1)
Chelation (1)
Chemical analysis (1)
Chemical modification (1)
Chromatography (1)
Computerized tomography (CT) (1)
Cryptic peptides (1)
Dichroism (1)
Drug products (1)
FAPI tumor volume (FAPI-TV) (1)
FDG-PET (1)
FDG-PET imaging (1)
Fludeoxyglucose (FDG) (1)
Fluorodeoxyglucose-positron emission tomography (FDG PET) (1)
Functional characterization (1)
Gastro-intestinal cancer (1)
GHR bioassay (1)
Growth hormone receptor (GHR) (1)
Highly active antiretroviral therapy (HAART) (1)
HIV infection (1)
Human growth hormone (1)
Hypoxia inducible factor-1 (HIF-1) (1)
Hypoxia-inducible factor-1alpha (HIF-1) (1)
Hypoxic tumor volume (HTV) (1)
Immunohistochemistry (IHC) (1)
Inherent complexity (1)
Intra-tumoral heterogeneity (1)
Isomers (1)
Lipodystrophy (1)
Loosening (1)
Lumbar fusion (1)
Lung lesions (1)
Mass spectrometry (1)
Medical imaging (1)
Metabolic tumor volume (MTV) (1)
Metastatic prostate carcinoma (1)
Multiple substitutions (1)
Native mass spectrometries (1)
Native MS (1)
Non-prostate carcinoma (1)
Overall survival (OS) (1)
Patient management (1)
Patienten management (1)
Pedicle screws (1)
Physico-chemical characterization (1)
Positron emission tomography/computed tomography (PET/CT) (1)
Primary prostate carcinoma (PPC) (1)
Progression-free survival (PFS) (1)
Proteins (1)
PSA response (1)
Pulmonary (1)
Quality control (1)
Racial differences (1)
Radioligand therapy (1)
Radiomics (1)
Recombinant human growth hormones (1)
SDG-03: Good health and well-being (1)